BT 20
Alternative Names: BT-20Latest Information Update: 03 Nov 2022
At a glance
- Originator Bone Therapeutics
- Developer BioSenic
- Class Mesenchymal stem cell therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Inflammation; SARS-CoV-2 acute respiratory disease